12 / 23
Page 35
Notes:
International Journal of Emergency Mental Health and Human Resilience | ISSN: 1522-4821 | Volume 20
November 26-27, 2018 | Los Angeles, USA
Psychiatry, Mental Health Nursing and Healthcare
World Summit on
Applied Psychology, Psychiatry and Mental Health
International Conference on
&
Protection of disease/conditions induced memory impairment by novel pharmaceutical agents
Karem H Alzoubi
1
and
Omar F Khabour
1,2
1
Jordan University of Science and Technology, Jordan
2
Taibah University, Saudi Arabia
M
emory impairment or dementia can be devastating and can lead to several complications. It can be precipitated as a result
of various diseases or conditions including Alzheimer’s disease, hypothyroidism, post-traumatic stress disorder, vascular
dementia, chronic stress, obesity, aging, sleep deprivation and consumption of high-fat high-carbohydrates diet, whereas
it can possibly be treated, various agents. The long-term goal of my studies is to explore novel pharmaceutical agents and
interventions that prevent or restores memory impairment induced by various diseases or conditions. In this presentation, I
will be discussing my latest results in a group of drugs including nicotine, L-thyroxin, pentoxifylline (PTX), caffeine, vitamin E
and C, tempol, etazolate, etc. These agents showed protective properties against memory impairment induced by chronic stress,
hypothyroidism, sleep deprivation, Alzheimer’s disease, post-traumatic stress disorder and obesity-induced by consumption
high-fat high-carbohydrates diet. Results presented are based on pre-clinical studies using standard or innovative animal
models of the above diseases or conditions superimposed with chronic drug treatment. Thereafter, behavioral studies were
conducted to test the spatial learning and memory using the Radial ArmWater Maze. Additionally, brain regions were usually
dissected; and levels/activities of important signaling molecules or biomarkers related to oxidative stress and inflammation will
be presented as possible molecular targets for the tested medications. Collectively, presented results will show the possibility
of treating or preventing cognitive impairment in various diseases and conditions via the chronic use of novel pharmaceutical
agents, which is probably achieved through normalizing the levels or activities of important signaling and biological biomarkers
within the hippocampus.
Biography
Karem H Alzoubi is a productive Scientist. He has published over 200 publications in distinguished international, scientific, peer-reviewed, indexed and refereed
journals or international conferences. Additionally, most of the scientific production of his is in journals with high impact factor relative to its area of specialization as
per the ISI Web Knowledge and Scopus databases. He has an H-index of 30 (Scopus, 2018). He has obtained his PhD degree in pharmacology from the College of
Pharmacy at the University of Houston, Texas, USA. He is now the Dean of the Faculty of Pharmacy at Jordan University of Science and Technology. He has been
awarded several national and international research and education excellence prizes. He had his pre-doctoral research in pharmacology, where he was trained on
state of the art techniques in behavioral and molecular neuroscience/neuropharmacology of cognitive functions. He has PI-ed or Co-PI-ed over 80 research grants
with success and published from every one of them.
khalzoubi@just.edu.joKarem H Alzoubi et al., Int J Emerg Ment Health, Volume 20
DOI: 10.4172/1522-4821-C5-023